Sugi Predict

Sugi Predict / Compounds / SCHEMBL2265622

SCHEMBL2265622

SCHEMBL2265622

CC1(C)OB(c2ccc(-c3ccccc3O)cc2)OC1(C)C

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LIPG Q9Y5X9 13/20 0.64
▸ LPL P06858 12/20 0.64
▸ ALDH1A1 P00352 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ BCL2L1 Q07817 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ P4HB P07237 1/20 0.43
▸ CA1 P00915 3/20 0.43
▸ CA2 P00918 3/20 0.43
▸ CA9 Q16790 3/20 0.43
▸ CA12 O43570 1/20 0.43
▸ CA3 P07451 1/20 0.43
▸ CA4 P22748 1/20 0.43
▸ CA6 P23280 1/20 0.43
▸ CA5A P35218 1/20 0.43
▸ CA7 P43166 1/20 0.43
▸ CA14 Q9ULX7 1/20 0.43
▸ CA5B Q9Y2D0 1/20 0.43
▸ F11 P03951 1/20 0.42
▸ PDGFRB P09619 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15456755 0.88 LIPG (0.75) LIPGLPLP4HBCA1CA2
SCHEMBL29871639 0.82 LIPG (0.62) LIPGLPLALDH1A1HPGDBCL2L1
SCHEMBL23303470 0.82 LIPG (0.62) LIPGLPLALDH1A1HPGDBCL2L1
SCHEMBL15973339 0.81 LIPG (0.66) LIPGLPLP4HBCA1CA2
SCHEMBL17411325 0.81 LIPG (0.61) LIPGLPLP4HBCA1CA2
SCHEMBL759136 0.81 LIPG (0.60) LIPGLPLALDH1A1HPGDBCL2L1
SCHEMBL29871636 0.81 LIPG (0.60) LIPGLPLALDH1A1HPGDBCL2L1
SCHEMBL30963065 0.80 LIPG (0.64) LIPGLPLP4HBCA1CA2
SCHEMBL3133101 0.80 LIPG (0.64) LIPGLPLALDH1A1HSD17B10P4HB
SCHEMBL28852276 0.80 LIPG (0.64) LIPGLPLP4HBCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688750-A1 SUBSTITUTED INDAZOLE PROPIONIC ACID DERIVATIVE COMPOUNDS AND USES THEREOF AS AMPK ACTIVATORS Pfizer Inc. (US) 2026-02-11 — — EP disclosed
US-20240336572-A1 SUBSTITUTED INDAZOLE PROPIONIC ACID DERIVATIVE COMPOUNDS AND USES THEREOF PFIZER INC. (US) 2024-10-10 — — US disclosed
WO-2024209363-A1 SUBSTITUTED INDAZOLE PROPIONIC ACID DERIVATIVE COMPOUNDS AND USES THEREOF AS AMPK ACTIVATORS PFIZER INC. (US) 2024-10-10 — — WO disclosed
US-11851429-B2 AMPK activators KALLYOPE, INC. (US) 2023-12-26 — — US disclosed
CN-113549010-B Preparation and application of compound with AMPK (AMPK) agonistic activity and prodrug thereof 中国科学院上海药物研究所 2023-10-20 — — CN disclosed
US-20220227754-A1 AMPK ACTIVATORS KALLYOPE, INC. 2022-07-21 — — US disclosed
US-11279702-B2 AMPK activators KALLYOPE, INC. (US) 2022-03-22 — — US disclosed
US-20220033401-A1 AMPK ACTIVATORS KALLYOPE, INC. 2022-02-03 — — US disclosed
WO-2021236617-A1 AMPK ACTIVATORS KALLYOPE, INC. (US) 2021-11-25 — — WO disclosed
US-9855260-B2 Quinolinone derivatives GLAXOSMITHKLINE LLC (US) 2018-01-02 — — US disclosed
US-20110195964-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2011-08-11 — — US disclosed
US-20110195964-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2011-08-11 — — US disclosed
EP-2352374-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS Merck Sharp & Dohme Corp. (US) 2011-08-10 — — EP disclosed
WO-2010051206-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2010-05-06 — — WO disclosed
WO-2010051176-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2010-05-06 — — WO disclosed
WO-2010051176-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2010-05-06 — — WO disclosed
WO-2010047982-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2010-04-29 — — WO disclosed
US-20100081643-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME LLC 2010-04-01 — — US disclosed
US-20100081643-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME LLC 2010-04-01 — — US disclosed
WO-2010036613-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2010-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240336572-A1 SUBSTITUTED INDAZOLE PROPIONIC ACID DERIVATIVE COMPOUNDS AND USES THEREOF PRKAG3, PRKAG1, PRKAG2 LIPG 3787/4885LPL 1586/4885ALDH1A1 912/4885
US-20220227754-A1 AMPK ACTIVATORS PRKAG1, PRKAG2, PRKAG3 LIPG 647/4885LPL 487/4885ALDH1A1 2034/4885
US-11279702-B2 AMPK activators PRKAG1, PRKAG2, PRKAG3 LIPG 647/4885LPL 487/4885ALDH1A1 2034/4885
US-20100081643-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS PRKAG2, PRKAG1, PRKAB2 LIPG 287/4885LPL 402/4885ALDH1A1 1887/4885
US-20220033401-A1 AMPK ACTIVATORS PRKAG1, PRKAG2, PRKAG3 LIPG 647/4885LPL 487/4885ALDH1A1 2034/4885
US-11851429-B2 AMPK activators PRKAG1, PRKAG2, PRKAG3 LIPG 647/4885LPL 487/4885ALDH1A1 2034/4885
US-20110195964-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS PRKAG2, PRKAG1, PRKAB2 LIPG 287/4885LPL 402/4885ALDH1A1 1887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.